News
Abzena announces appointment of Petra Dieterich as Scientific Lead
Abzena, the leading Partner Research Organization (PRO) providing integrated discovery, development and manufacturing of biologics and antibody drug conjugates (ADCs) has announced the appointment of Dr. Petra Dieterich, DPhil, MBA, as scientific lead.
Reporting to Abzena’s chief technology officer Dr....
News
In Preserved Ejection Fraction Trial Farxiga Shows Depth
DELIVER is the world's largest study of heart failure with intact ejection fraction. The DELIVER phase 3 trial produced favourable findings for AstraZeneca. It showed that Farxiga (dapagliflozin) reduced the primary outcome of cardiovascular death or deteriorating heart failure...
IT & Data Management
Ashfield Engage acquires smart data organization PROPENSITY4
Ashfield Engage, part of UDG Healthcare has acquired PROPENSITY4 - a ‘smart data’ organization and leader in the healthcare insights and analytics arena.
PROPENSITY4 integrates internal and external data assets and applies the right methodologies to derive detailed insight using...
Drug Research
Citius Pharma selects global CRO, Biorasi to help expand phase 3 Mino-Lok trial to additional sites outside US
Citius Pharmaceuticals, Inc., a late-stage biopharmaceutical company, announced that it has selected Biorasi, LLC (Biorasi), a global clinical research organization (CRO), to help expand the company's phase 3 Mino-Lok trial to additional sites outside the United States. If approved,...
News
Sanofi Drug Ingredients Startup Takes off After Two Years
It's a fact: EUROAPI debuted on the Euronext exchange two years and one pandemic after Sanofi announced plans to sell off its European pharma ingredients division. Even though the market as a whole was going down, shares of the...
News
Novartis Halts Cancer Radiotherapy Output Due To Quality
Novartis has halted production of its two commercial radioligand treatments for cancer care just weeks after the FDA approved them.
Novartis confirmed on May 5th that production of Lutathera, a neuroendocrine tumour medication, and Pluvicto, a newly approved prostate cancer...
News
FDA Stalls The Use of J&J COVID Jab Due To Thrombosis Risk
The US Food and Drug Administration recently announced that the Johnson & Johnson/Janssen COVID-19 vaccine's urgent use permit will be restricted to people 18 or older for whom other vaccines are really not suitable or available, as well as...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read